Respond to prefers-color-scheme dark in app web views

Follow section front redirects in Spectrum

Enable NLP source in PCS for load testing

Switch off the News Alerts Survey Widget when we have enough responses

Poll to determine if new LUF updates are available

Allows the winning A/B test variant to be turned on without Spectrum deployment

Show infinite scrolling sections in Assembler MultiView

Show option for NLP article summaries in Action Bar

Show NLP summaries collection recirc on article pages

A general feature flag for Recipe Features that aren't yet released

Feature flag for media team features that aren't yet released

Use new Orca video player for preroll plugin in Spectrum

Show the snow tracker (instead of the heat tracker) on Spectrum

How Jim Jordan tried to connect the dots on Biden’s $8 million book deal

‘Never Trump?’ ‘Never Biden’ voters might loom larger.

Ukraine gamble pays off: Republicans face little backlash in primaries

The world’s coolest hotels want to tell you a story

Cruise ships to return to Baltimore two months after bridge collapse 

Some cruise prices are about to get a little more clear

At campus protests, ‘DO NOT TALK TO THE MEDIA’!

Trump’s lawyer charges Michael Cohen lied to jury

CNN gets a presidential debate — and a much-needed win

She finished chemo then got a medical degree: ‘The dream is real now’

Puppy abandoned with heart-rending note is adopted, named Minerva

Man, 91, shocks tiny firehouse with $500K gift: ‘Nobody knew how much I’d saved’

Carolyn Hax: Is it weird to ask other people to care about you?

Ask Amy: Can’t a single woman eat alone without interruption?

Miss Manners: Miss Manners: Gag gift falls flat

Russia shows resilience. There is more to do for Ukraine.

Trump promises tax cuts and fewer rules. CEOs shouldn’t fall for it.

Tariffs against China hamstring the transition to a clean energy future

Biden’s false claim that inflation was 9 percent when he took office

Did Obamacare ‘massively’ increase the cost of health care?

Blue Origin to fly again as space tourism struggles to get off the ground

These ISIS news anchors are AI fakes. Their propaganda is real.

Boeing delays spaceflight again as it continues to struggle with leak

Book Tour: At home with Amor Towles

In photos: The scene in Houston after severe storms killed at least 7 people

Civilians flee new Russian attacks on Ukraine border

Joey Gallo returns, but Nats endure another quiet offensive night

Bryce Harper, Joey Gallo and a bond forged by baseball since they were kids

A taco will always be a taco — no matter what we call it

Mexican taquería’s new Michelin star puts street eats on par with gourmet food

Police believe a U.S. rapist killed several women in Canada

With its energy network nearly destroyed, Ukraine already fears the winter

Trump

There's widespread outrage about soaring drug prices, but a new report shows that people are, on average, actually paying less for their medications than they did a few years ago.

Drug prices are on the upswing, with net prices rising 3.5 percent last year, according to the study from the QuintilesIMS Institute, a research organization that specializes in health care analysis. And total spending climbed to $323 billion, even after accounting for all the discounts and rebates that drugmakers provide. But patients' out-of-pocket costs for medicines have declined, from $32 per name-brand prescription in 2013 to $28 today.

The report, which did not receive industry funding, isn't the only one to show this counterintuitive pattern of declining out-of-pocket costs. A <a href="http://www.healthsystemtracker.org/insight/examining-high-prescription-drug-spending-for-people-with-employer-sponsored-health-insurance/">Peterson-Kaiser Health System Tracker</a> report last year found a slight decline in patients' personal spending on prescriptions, even as the overall costs increased.

These are the kinds of numbers the pharmaceutical industry typically uses to defend itself against criticisms of price gouging, asking people to look away from list prices that <a href="https://www.washingtonpost.com/business/this-drug-is-defying-a-rare-form-of-leukemia--and-it-keeps-getting-pricier/2016/03/09/4fff8102-c571-11e5-a4aa-f25866ba0dc6_story.html">continually rise</a>. Indeed, the new report found that average name brand drug list prices rose from $230 to $341 over the four-year period — even as the out-of-pocket costs for patients slightly decreased.

But if patients are so well insulated from those rising prices, why do so many people feel prescription drug costs have spiraled out of control?

The answer lies in the extremes: On the low-end of the average are an increasing number of prescriptions that have zero dollar out-of-pocket costs. Some of those include preventive medicines that were required by the Affordable Care Act to be made available to patients for free, such as birth control. The proportion of prescriptions with a $0 co-pay has risen from 23.6 percent of prescriptions in 2013 to nearly 30 percent last year.

On the high-end of the average are the people who are exposed to the ever-rising list prices of drugs through deductibles or coinsurance. According to the new report, nearly 1 in 5 brand name drug prescriptions are paid for through deductibles and coinsurance, but those people shouldered a little more than half of the out-of-pocket spending. About a third of high-priced specialty drugs are paid for through coinsurance and deductibles, but patients who filled those prescriptions took on 91 percent of out-of-pocket spending.

The proportion of prescriptions that cost more than $50 to a patient shrank slightly, from 2.7 percent of prescriptions in 2013 to 2.3 percent last year.

Part of this has to do with the steps the pharmaceutical industry has taken to subsidize its own products. The study examined a subset of drugs and found that the use of coupons to reduce patients' out-of-pocket costs had climbed to nearly 1 in 5 drugs. Insurers and the companies they hire to negotiate with drug companies on prices, called pharmacy benefit managers, dislike these coupons, because they argue they allow patients to utilize more expensive drugs, even when cheaper substitutes are available.

Drug companies like to accuse insurers of saddling consumers with these kinds of plans. Insurers turn the blame around and argue that if drug companies didn't keep raising the list prices of drugs, the patients wouldn't face such high bills.

In the middle of all the finger-pointing are consumers, who also bear the negative consequences. Even though out-of-pocket payments for drugs are slightly down, rising insurance premiums spread the costs over everyone else. And the report shows that when patients face the upfront costs of medication through deductibles, they are far more likely to not fill their prescriptions at all.

When a name brand drug's cost is in the deductible, they are 2.5 times more likely to walk away from the pharmacy counter than people who don't face a deductible.

Finalist for the 2013 Pulitzer Prize in national reporting, as part of a team

Amherst College, BA in Physics and English

MIT, MS in Science Writing

Carolyn Johnson is a science reporter. She previously covered the business of health and the affordability of health care to consumers. 

Carolyn Y. Johnson

The Washington Post

name

prism://prism.query/site,/us-policy/economic-policy&limit=20

Economic Policy

prism://prism.query/site,/us-policy&limit=20

U.S. Policy

Policy

News, video and analysis of government, economic, climate, foreign, technology and health policy in the United States.